British Patient Capital

British Patient Capital invests in a diversified portfolio of best-in-class venture and growth capital funds and start ups, capturing value through financing the growth of innovative companies. We invest on a commercial basis to deliver competitive returns and manage risk.

As well as providing our own funding we work to encourage more investors to make allocations to this asset class by demonstrating that a long-term patient capital investment strategy can produce commercially attractive returns.

Once we’ve established a strong record, and have proved the value of the asset class, we intend to privatise British Patient Capital at an appropriate time in the future.

British Patient Capital, established in 2018 and headquartered in Europe., specializes in Early Stage Venture, Late Stage Venture investments across Biotechnology, Life Science, Therapeutics, Financial Services, Venture Capital, Health Care, Pharmaceutical, Medical, Finance, FinTech. The organization boasts a portfolio of 26 investments, with an average round size of $69.9M and 1 successful exits. Their recent investments include Myricx Bio, Brandon Capital, Eli Lilly, Novo Holdings, Abingworth. The highest investment round they participated in was $222.4B. Among their most notable exits are Myricx Bio and Brandon Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.